Results 231 to 240 of about 152,418 (295)

New perspectives on VEGF signalling in Alzheimer's disease

Brain Pathology, EarlyView.
Emery et al. bring together findings from recent multi‐omic studies, including single‐cell mRNA analysis of human post‐mortem brain tissue, and proteomic analysis of matched CSF and blood samples in large clinical studies. The authors present evidence of the involvement of altered VEGF signalling in vascular and immune dysfunction and neurodegeneration
Cherelle E. G. Emery, Seth Love, J. Scott Miners   +2 more
wiley   +1 more source

Adult neurogenesis in the ventral hippocampus decreased among animal models of neurodevelopmental disorders. [PDF]

Front Neural Circuits
Sun L, Ohashi N, Mori T, Mizuno Y, Zang W, Guo Q, Kouyama-Suzuki E, Shirai Y, Tabuchi K.   +8 more
europepmc   +1 more source

Human brain matters: Navigating the neuropathology of COVID‐19

Brain Pathology, EarlyView.
Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland, Angelica Scaramuzza, Marianna Bugiani, Wilma D. J. van de Berg, Jinte Middeldorp   +4 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Switching of RNA splicing regulators in immature neuroblasts during adult neurogenesis. [PDF]

Elife
Bernou C, Mouthon MA, Daynac M, Kortulewski T, Demaille B, Barroca V, Couillard-Despres S, Dechamps N, Ménard V, Bellenger L, Antoniewski C, Chicheportiche AD, Boussin FD.   +12 more
europepmc   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Human adult neurogenesis loss corresponds with cognitive decline during epilepsy progression. [PDF]

Cell Stem Cell
Ammothumkandy A, Corona L, Ravina K, Wolseley V, Nelson J, Atai N, Abedi A, Jimenez N, Armacost M, D'Orazio LM, Zuverza-Chavarria V, Cayce A, McCleary C, Nune G, Kalayjian L, Lee DJ, Lee B, Chow RH, Heck C, Russin JJ, Liu CY, Smith JAD, Bonaguidi MA.   +22 more
europepmc   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

In rats, neurodevelopmental disorders induced by maternal hypoxia are associated with attenuated excitatory neurotransmission in the cingulate cortex

British Journal of Pharmacology, EarlyView.
Background and Purpose Maternal hypoxia is a recognised risk factor for neurodevelopmental disorders in offspring. Although rodent models of hypoxia have been reported, the detailed pathogenesis of maternal hypoxia‐induced neurodevelopmental disorders remains unclear.
Kentaro Tokudome, Masaaki Ueki, Takujiro Homma, Shinji Matsunaga, Saki Shimizu, Yukihiro Ohno, Shuhei Tomita   +6 more
wiley   +1 more source